Impax Laboratories revenues surge in Q3
Impax has posted a net income of $75.16m for the third quarter 2010, or $1.15 per diluted share, compared to $6.69m, or $0.11 per diluted share, for the
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
As per the terms of the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca